Sellas Life Sciences Group Inc (SLS)
Healthcare
Biotechnology
—
11.20 $
+12.1%
vs. previous close
Closing price · As of: 3. Aug 2026
Sellas Life Sciences Group Inc (SLS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -28 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -43 | -48 | -45 | -11 | -30 | -18 | -10 | -26 | -24 | -31 | -35 | -28 | |
| 0.9 | 0.4 | 0.1 | 0.0 | 3.8 | 1.7 | 0.3 | 5.7 | 0.5 | – | – | – | |
| 5.4 | 1.9 | 2.3 | 3.2 | 0.4 | 0.6 | 0.6 | 1.0 | 1.7 | 1.4 | 1.6 | 2.0 | |
| 5.6 | -7.1 | -9.2 | 6.4 | 7.5 | 3.3 | 0.8 | 2.3 | 12 | – | – | – | |
| 4.0 | 20 | -25 | 6.1 | -10 | -1.1 | 5.6 | -7.6 | 5.6 | 3.3 | -6.6 | -4.1 | |
| 5.5 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.5 | 5.5 | 0.0 | 0.0 | |
| -5.5 | 10 | -1.1 | 1.8 | – | -4.5 | -4.5 | -4.5 | -4.5 | -5.5 | – | – | |
| 0.0 | 0.5 | 0.5 | 0.7 | 0.5 | 0.0 | – | – | – | – | – | – | |
| 26 | 47 | 34 | 0.5 | 31 | 20 | 38 | – | – | 0.0 | – | – | |
| -1.8 | -3.9 | 18 | -0.5 | -7.6 | – | – | – | – | – | – | – | |
| 24 | 44 | 34 | 5.5 | 23 | 20 | 38 | 12 | 24 | 22 | 47 | 86 | |
| -24 | 6.1 | -12 | -3.6 | -7.3 | 1.9 | 28 | -14 | -4.2 | -15 | 11 | 58 | |
| -48 | -48 | -45 | -11 | -30 | -18 | -10 | -26 | -28 | -37 | -35 | -28 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.